{
    "Disease activity (follow up: 2 years; assessed with: ACR 20 )": {
        "No of studies": ["1", "2"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": ["serious", "b"],
        "Indirectness": ["serious", "c"],
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["207/467 (44.3%)", "e"],
            "MTX monotherapy": "205/459 (44.7%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.99 (0.86 to 1.15)",
            "Absolute (95% CI)": "4 fewer per 1,000 (from 63 fewer to 67 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "CRITICAL"
    },

    "Disease activity (follow up: 2 years; assessed with: ACR 50)": {
        "No of studies": ["1", "2"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": ["serious", "f"],
        "Indirectness": ["serious", "c"],
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["188/451 (41.7%)", "e"],
            "MTX monotherapy": "182/426 (42.7%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.98 (0.84 to 1.14)",
            "Absolute (95% CI)": "9 fewer per 1,000 (from 68 fewer to 60 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "CRITICAL"
    },

    "Disease activity (follow up: 2 years; assessed with: ACR 70)": {
        "No of studies": ["1", "2"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["128/451 (28.4%)", "e"],
            "MTX monotherapy": "113/426 (26.5%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.07 (0.86 to 1.33)",
            "Absolute (95% CI)": "19 more per 1,000 (from 37 fewer to 88 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "CRITICAL"
    },

    "Remission (follow up: 2 years; assessed with: DAS28-ESR <2.6)": {
        "No of studies": "2",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["69/274 (25.2%)", "e"],
            "MTX monotherapy": "64/257 (24.9%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.01 (0.75 to 1.36)",
            "Absolute (95% CI)": "2 more per 1,000 (from 62 fewer to 90 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "CRITICAL"
    },

    "Radiographic progression (follow up: 2 years; assessed with: mTSS (Lower values – > benefit) (MCID 4.6)": {
        "No of studies": "1",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["177", "e"],
            "MTX monotherapy": "169"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": ["MD 1.9 lower (3.19 lower to 0.61 lower)", "g"]
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "CRITICAL"
    },

    "Disability (follow up: range 1 year to 2 years; assessed with: HAQ-DI (Lower values – > benefit) (MCID -0.22)": {
        "No of studies": ["2", "3"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["481", "e"],
            "MTX monotherapy": "474"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": ["MD 0.01 higher (0.07 lower to 0.1 higher)", "h"]
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Fatigue (follow up: 2 years; assessed with: FACIT-F (Higher values – > benefit) (MCID 15.9)": {
        "No of studies": "4",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["272", "e"],
            "MTX monotherapy": "254"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 1.7 lower (3.09 lower to 0.31 lower)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Pain (follow up: 2 years; assessed with: VAS 0-100 (Lower values – > benefit) (MCID -11.9)": {
        "No of studies": "5",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["273", "e"],
            "MTX monotherapy": "256"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 7.1 higher (4.34 higher to 9.86 higher)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 PCS (Higher values – > benefit) (MCID 4.4)": {
        "No of studies": ["3", "5"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": ["serious", "i"],
        "Indirectness": ["serious", "c"],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": "471",
            "MTX monotherapy": "464"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.56 lower (1.73 lower to 0.6 higher)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Quality of life (follow up: range 1 year to 2 years; assessed with: SF-36 MCS (Higher values – > benefit) (MCID 3.1)": {
        "No of studies": ["3", "5"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": ["not serious", "j"],
        "Indirectness": ["serious", "c"],
        "Imprecision": ["serious", "k"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": "471",
            "MTX monotherapy": "464"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 1.98 lower (3.18 lower to 0.78 lower)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Serious adverse events (follow up: 2 years)": {
        "No of studies": "2",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": ["serious", "k"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["92/274 (33.6%)", "e"],
            "MTX monotherapy": "68/257 (26.5%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.27 (0.98 to 1.65)",
            "Absolute (95% CI)": "71 more per 1,000 (from 5 fewer to 172 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Withdrawal due to lack of efficacy (2 years)": {
        "No of studies": ["1", "2"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["68/481 (14.1%)", "e"],
            "MTX monotherapy": "69/474 (14.6%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.95 (0.70 to 1.30)",
            "Absolute (95% CI)": "7 fewer per 1,000 (from 44 fewer to 44 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Withdrawal due to adverse events (follow up: 2 years)": {
        "No of studies": ["1", "2"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": ["serious", "l"],
        "Indirectness": ["serious", "c"],
        "Imprecision": ["very serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["41/481 (8.5%)", "e"],
            "MTX monotherapy": "46/474 (9.7%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.88 (0.59 to 1.32)",
            "Absolute (95% CI)": "12 fewer per 1,000 (from 40 fewer to 31 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Death (follow up: 2 years)": {
        "No of studies": "2",
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": ["serious", "m"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["4/274 (1.5%)", "e"],
            "MTX monotherapy": "1/257 (0.4%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 3.75 (0.42 to 33.35)",
            "Absolute (95% CI)": "11 more per 1,000 (from 2 fewer to 126 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Malignancy (follow up: 2 years)": {
        "No of studies": ["1", "2"],
        "Study design": "randomised trials",
        "Risk of bias": ["serious", "a"],
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "c"],
        "Imprecision": ["serious", "m"],
        "Other considerations": "none",
        "Nº of patients": {
            "TNF inhibitor": ["8/481 (1.7%)", "e"],
            "MTX monotherapy": "7/474 (1.5%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.13 (0.41 to 3.08)",
            "Absolute (95% CI)": "2 more per 1,000 (from 9 fewer to 31 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },

    "Malignancy (from SRs on harms)": {
        "No of studies": "6",
        "content": "The systematic review RefID=3394, 2014 (RCTs=28, n=11741) comparing any TNFi vs placebo + MTX among RA showed that for cancer, the result was OR=1.30 (95% CI 0.80,2.14 Modified ITT model) [OR=1.06 (95% CI 0.64,1.75; p=0.82) Per protocol model]"
    },

    "Cardiovascular disease (from SRs on harms)": {
        "No of studies": "7",
        "content": "The systematic review RefID=1105, 2017 (NRS=7, n=49003) comparing any TNFi vs csDMARDs among RA showed that for Cardiovascular disease, the result was RR = 0.62 (95% CI 0.44–0.88), p=0.007"
    },

    "Death (from SRs on harms)": {
        "No of studies": "7",
        "content": "The systematic review RefID=1105, 2017 (NRS=5, n=41579) comparing any TNFi vs csDMARD among RA showed that for Death, the result was RR = 0.60 (95% CI 0.38–0.94), p=0.03"
    }
}